| 000 | 03437nlm1a2200409 4500 | ||
|---|---|---|---|
| 001 | 664912 | ||
| 005 | 20231030041945.0 | ||
| 035 | _a(RuTPU)RU\TPU\network\36097 | ||
| 090 | _a664912 | ||
| 100 | _a20210528a2021 k y0engy50 ba | ||
| 101 | 0 | _aeng | |
| 135 | _adrcn ---uucaa | ||
| 181 | 0 | _ai | |
| 182 | 0 | _ab | |
| 200 | 1 |
_a66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26 _fS. S. Rinne, A. Abouzayed, K. Gagnon [et al.] |
|
| 203 |
_aText _celectronic |
||
| 300 | _aTitle screen | ||
| 320 | _a[References: 49 tit.] | ||
| 330 | _aMolecular imaging of the gastrin-releasing peptide receptor (GRPR) could improve patient management in prostate cancer. This study aimed to produce gallium-66 (T½ = 9.5 h) suitable for radiolabeling, and investigate the imaging properties of gallium-66 labeled GRPR-antagonist NOTA-PEG2-RM26 for later-time point PET-imaging of GRPR expression. Gallium-66 was cyclotron-produced using a liquid target, and enriched [66Zn]Zn(NO3)2. In vitro, [66Ga]Ga-NOTA-PEG2-RM26 was characterized in GRPR-expressing PC-3 prostate cancer cells. In vivo, specificity test and biodistribution studies were performed 3 h and 22 h pi in PC-3 xenografted mice. microPET/MR was performed 3 h and 22 h pi. Biodistribution of [66Ga]Ga-NOTA-PEG2-RM26 was compared with [68Ga]Ga-NOTA-PEG2-RM26 3 h pi. [66Ga]Ga-NOTA-PEG2-RM26 was successfully prepared with preserved binding specificity and high affinity towards GRPR. [66Ga]Ga-NOTA-PEG2-RM26 cleared rapidly from blood via kidneys. Tumor uptake was GRPR-specific and exceeded normal organ uptake. Normal tissue clearance was limited, resulting in no improvement of tumor-to-organ ratios with time. Tumors could be clearly visualized using microPET/MR. Gallium-66 was successfully produced and [66Ga]Ga-NOTA-PEG2-RM26 was able to clearly visualize GRPR-expression both shortly after injection and on the next day using PET. However, delayed imaging did not improve contrast for Ga-labeled NOTA-PEG2-RM26. | ||
| 461 | _tScientific Reports | ||
| 463 |
_tVol. 11, iss. 1 _v[3631, 12 p.] _d2021 |
||
| 610 | 1 | _aэлектронный ресурс | |
| 610 | 1 | _aтруды учёных ТПУ | |
| 610 | 1 | _aparticle physics | |
| 610 | 1 | _aprostate cancer | |
| 610 | 1 | _aфизика | |
| 610 | 1 | _aчастицы | |
| 610 | 1 | _aрак | |
| 701 | 1 |
_aRinne _bS. S. _gSara |
|
| 701 | 1 |
_aAbouzayed _bA. _gAyman |
|
| 701 | 1 |
_aGagnon _bK. _gKatherine |
|
| 701 | 1 |
_aTolmachev _bV. M. _cspecialist in the field of medical technology _cDirector of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D _f1961- _gVladimir Maksimilianovich _2stltpush _3(RuTPU)RU\TPU\pers\46552 |
|
| 701 | 1 |
_aOrlova _bA. M. _cspecialist in the field of medical technology _cSenior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D _f1960- _gAnna Markovna _2stltpush _3(RuTPU)RU\TPU\pers\46554 |
|
| 712 | 0 | 2 |
_aНациональный исследовательский Томский политехнический университет _bИсследовательская школа химических и биомедицинских технологий _bНаучно-исследовательский центр "Онкотераностика" _h8442 _2stltpush _3(RuTPU)RU\TPU\col\27561 |
| 801 | 2 |
_aRU _b63413507 _c20220316 _gRCR |
|
| 856 | 4 | _uhttps://doi.org/10.1038/s41598-021-82995-7 | |
| 942 | _cCF | ||